SCHEMBL4056469

SCHEMBL4056469

COc1ccc(Cc2nc3ncc(-c4ccccc4)cc3[nH]2)cc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.54
NOS1 P29475 1/20 0.54
NOS2 P35228 1/20 0.54
POLB P06746 1/20 0.50
PDGFRB P09619 2/20 0.41
PDGFRA P16234 2/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
GRIN1 Q05586 1/20 0.40
GRIN2B Q13224 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
AURKA O14965 1/20 0.39
PDE10A Q9Y233 2/20 0.38
USP30 Q70CQ3 2/20 0.37
KIT P10721 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4053584 0.92 POLB (0.60) NOS3NOS1NOS2POLBPDGFRB
SCHEMBL4049571 0.86 POLB (0.46) NOS3NOS1NOS2POLBLMNA
SCHEMBL4052457 0.85 NOS3 (0.63) NOS3NOS1NOS2LMNASMN1; SMN2
SCHEMBL4055977 0.84 POLB (0.43) NOS3NOS1NOS2POLBLMNA
SCHEMBL4050809 0.83 NOS3 (0.64) NOS3NOS1NOS2LMNASMN1; SMN2
SCHEMBL4058869 0.83 RXFP1 (0.54) NOS3NOS1NOS2POLBLMNA
SCHEMBL13608262 0.82 POLB (0.50) POLBPDGFRBPDGFRALMNASMN1; SMN2
SCHEMBL4055576 0.82 NOS3 (0.54) NOS3NOS1NOS2LMNASMN1; SMN2
SCHEMBL4053324 0.82 POLB (0.53) NOS3NOS1NOS2POLBPDGFRB
SCHEMBL4052000 0.81 NOS1 (0.61) NOS3NOS1NOS2POLBPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NOS3 907/4885NOS1 879/4885NOS2 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.